Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
German Wound CongressGerman Wound Congress
Not Confirmed
Not Confirmed
07 April-09 May, 2025
Not Confirmed
Not Confirmed
08 April-11 May, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
German Wound CongressGerman Wound Congress
Industry Trade Show
Not Confirmed
07 April-09 May, 2025
Industry Trade Show
Not Confirmed
08 April-11 May, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/how-trump-s-tariffs-on-imported-drugs-can-hurt-supply-chains-consumers-and-industry
12 Nov 2024
// PRESS RELEASE
https://mabxience.com/mabxience-and-egis-enter-strategic-license-agreement-for-biosimilar-candidates-in-key-central-and-eastern-european-markets/
03 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/03/2957702/0/en/Teva-and-mAbxience-Expand-Strategic-Partnership-to-include-an-additional-Oncology-Biosimilar-Candidate.html
10 May 2024
// CONTRACT PHARMA
https://www.contractpharma.com/contents/view_breaking-news/2024-05-10/mabxience-names-new-chief-executive-officer/?widget=listSection
09 May 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/mabxience-appoints-jurgen-van-broeck-as-new-ceo-302141331.html
16 Apr 2024
// Catherine Eckford EUROPEAN PHARMACEUTICAL REVIEW
https://www.europeanpharmaceuticalreview.com/news/226663/teva-enters-into-oncology-biosimilar-licensing-agreement/
04 Apr 2024
// BUSINESSWIRE
Details:
mAbxience will manufacture the biosimilar of Fabrazyme (agalsidase beta), developed by Biosidus, for Fabry disease treatment under the agreement.
Lead Product(s): Agalsidase Beta
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Cell and Gene therapy
Sponsor: Biosidus
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 02, 2024
Lead Product(s) : Agalsidase Beta
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Biosidus
Deal Size : Undisclosed
Deal Type : Agreement
mAbxience and Biosidus Sign CDMO agreement for agalsidase beta in Fabry disease
Details : mAbxience will manufacture the biosimilar of Fabrazyme (agalsidase beta), developed by Biosidus, for Fabry disease treatment under the agreement.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 02, 2024
Details:
mAbxience will leverage its expertise in biosimilar development to develop and produce the biosimilar product currently in development for the treatment of multiple oncology indications.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Undisclosed
Sponsor: Teva Pharmaceutical Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 04, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Teva Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Teva and mAbxience Announce Global Licensing Deal for an Oncology Biosimilar Candidate
Details : mAbxience will leverage its expertise in biosimilar development to develop and produce the biosimilar product currently in development for the treatment of multiple oncology indications.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 04, 2024
Details:
Under the agreement, Intas receives exclusive rights to commercialise Etanercept biosimilars, through its affiliates, for the treatment of various autoimmune diseases, in more than 150 countries across the globe, including Europe and the United States of America.
Lead Product(s): Etanercept
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Protein
Sponsor: Intas Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 20, 2023
Lead Product(s) : Etanercept
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Intas Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Intas receives exclusive rights to commercialise Etanercept biosimilars, through its affiliates, for the treatment of various autoimmune diseases, in more than 150 countries across the globe, including Europe and the United States of...
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
December 20, 2023
Details:
Under the terms of agreement, mAbxience will fully develop the biosimilar, Denosumab (ref Prolia and XGEVA) and manufacture in it's GMP-approved facilities, while Amneal will guide the product through regulatory approval and have exclusive commercialization rights in the US.
Lead Product(s): Denosumab
Therapeutic Area: Musculoskeletal Brand Name: MB-09
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Amneal Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 10, 2023
Lead Product(s) : Denosumab
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Amneal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio
Details : Under the terms of agreement, mAbxience will fully develop the biosimilar, Denosumab (ref Prolia and XGEVA) and manufacture in it's GMP-approved facilities, while Amneal will guide the product through regulatory approval and have exclusive commercializat...
Product Name : MB-09
Product Type : Antibody
Upfront Cash : Undisclosed
December 10, 2023
Details:
Under the agreemeent, Abbott will commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia, the Middle East and Africa, and mAbxience will develop, manufacture and supply the biosimilar molecules.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Undisclosed
Sponsor: Abbott Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 20, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Abbott Laboratories
Deal Size : Undisclosed
Deal Type : Agreement
Abbott Broadens Access to Cutting-edge Biosimilars in Key Emerging Markets
Details : Under the agreemeent, Abbott will commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia, the Middle East and Africa, and mAbxience will develop, manufacture and supply the biosimilar molecules.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 20, 2023
Details:
U.S.FDA has approved Company’s Biologics License Application for bevacizumab-maly, is a vascular endothelial growth factor inhibitor, a biosimilar referencing Avastin for first or second-line treatment metastatic colorectal cancer.
Lead Product(s): Bevacizumab
Therapeutic Area: Oncology Brand Name: Alymsys
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Amneal Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 13, 2022
Lead Product(s) : Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Amneal Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)
Details : U.S.FDA has approved Company’s Biologics License Application for bevacizumab-maly, is a vascular endothelial growth factor inhibitor, a biosimilar referencing Avastin for first or second-line treatment metastatic colorectal cancer.
Product Name : Alymsys
Product Type : Antibody
Upfront Cash : Inapplicable
April 13, 2022
Details:
mAbxience has developed and manufactured biological drugs, with commercialized biosimilar product Novex® (Rituximab), through its in-house biosimilars programs and through its investment in mAbxience Fresenius expects rapid growth in biopharmaceutical market.
Lead Product(s): Rituximab,Cyclophosphamide,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Brand Name: Novex
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Fresenius Kabi AG
Deal Size: $553.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition March 31, 2022
Lead Product(s) : Rituximab,Cyclophosphamide,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Fresenius Kabi AG
Deal Size : $553.0 million
Deal Type : Acquisition
Fresenius Kabi Buys a Majority Stake In mAbxience
Details : mAbxience has developed and manufactured biological drugs, with commercialized biosimilar product Novex® (Rituximab), through its in-house biosimilars programs and through its investment in mAbxience Fresenius expects rapid growth in biopharmaceutical m...
Product Name : Novex
Product Type : Antibody
Upfront Cash : Undisclosed
March 31, 2022
Details:
mAbxience has developed and manufactured biological drugs, with commercialized biosimilar product Novex® (rituximab), through its in-house biosimilars programs and through its investment in mAbxience, Fresenius expects rapid growth in biopharmaceutical market.
Lead Product(s): Rituximab
Therapeutic Area: Oncology Brand Name: Novex
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Fresenius Kabi AG
Deal Size: $553.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 08, 2022
Lead Product(s) : Rituximab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Fresenius Kabi AG
Deal Size : $553.0 million
Deal Type : Acquisition
Details : mAbxience has developed and manufactured biological drugs, with commercialized biosimilar product Novex® (rituximab), through its in-house biosimilars programs and through its investment in mAbxience, Fresenius expects rapid growth in biopharmaceutical ...
Product Name : Novex
Product Type : Antibody
Upfront Cash : Undisclosed
January 08, 2022
Details:
Alymsys (bevacizumab-maly) is a vascular endothelial growth factor inhibitor for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first or second-line treatment.
Lead Product(s): Bevacizumab,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Brand Name: Alymsys
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Zentiva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 04, 2021
Lead Product(s) : Bevacizumab,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Zentiva
Deal Size : Undisclosed
Deal Type : Collaboration
Zentiva Continues Its Expansion in Oncology with The Launch of Alymsys® (Bevacizumab) in 21 Count...
Details : Alymsys (bevacizumab-maly) is a vascular endothelial growth factor inhibitor for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first or second-line treatment.
Product Name : Alymsys
Product Type : Antibody
Upfront Cash : Undisclosed
September 04, 2021
ABOUT THIS PAGE